The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Open accessAbstract
Alzheimer’s disease (AD) is the most common type of dementia, and promptly diagnosis of AD is crucial for delaying the development of disease and improving patient quality of life. However, AD detection, particularly in the early stages, remains a substantial challenge due to the lack of specific biomarkers. The present study was undertaken to identify and validate the potential of circulating miRNAs as novel biomarkers for AD. Solexa sequencing was employed to screen the expression profile of serum miRNAs in AD and controls. RT-qPCR was used to confirm the altered miRNAs at the individual level. Moreover, candidate miRNAs were examined in the serum samples of patients with mild cognitive impairment (MCI) and vascular dementia (VD). The results showed that four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were markedly decreased in AD patients’ serum compared with controls. Receiver operating characteristic curve analysis demonstrated that this panel of four miRNAs could be used as potential biomarker for AD. Furthermore, miR-93, and miR-146a were significantly elevated in MCI compared with controls, and the panel of miR-31, miR-93 and miR-146a can be used to discriminate AD from VD. We established a panel of four serum miRNAs as a novel noninvasive biomarker for AD diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Hachinski, V., Iadecola, C., Petersen, R. C., Breteler, M. M., Nyenhuis, D. L., Black, S. E., Powers, W. J., DeCarli, C., Merino, J. G., Kalaria, R. N., et al. (2006) · Stroke · doi:10.1161/01.str.0000237236.88823.47 · Cited by 1,722
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183
Ng, E. K. O., Chong, W. W. S., Jin, H., Lam, E. K. Y., Shin, V. Y., Yu, J., Poon, T. C. W., Ng, S. S. M., & Sung, J. J. Y. (2009) · Gut · doi:10.1136/gut.2008.167817 · Cited by 1,151
Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., Kelnar, K., Kemppainen, J., Brown, D., Chen, C., et al. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14103 · Cited by 943 · cited 1×
“Another study reported that the expression levels of miRNA in AD patients’ brains and cerebrospinal fluid (CSF) were also deregulated; this study also reported the discovery of AD-specific miRNA as potential biomarkers [26].”
ResultLukiw, W. J., Zhao, Y., & Cui, J. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805371200 · Cited by 441
Cited by
Current understanding of Alzheimer’s disease diagnosis and treatment
Weller, J., & Budson, A. (2018) · F1000Research · doi:10.12688/f1000research.14506.1 · Cited by 1,083
Post-stroke dementia – a comprehensive review
Mijajlović, M. D., Pavlović, A., Brainin, M., Heiss, W.-D., Quinn, T. J., Ihle-Hansen, H. B., Hermann, D. M., Assayag, E. B., Richard, E., Thiel, A., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0779-7 · Cited by 693
Wang, T., Shao, W., Huang, Z., Tang, H., Zhang, J., Ding, Z., & Huang, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23774-w · Cited by 671
Self-citationChung, H. Y., Kim, D. H., Lee, E. K., Chung, K. W., Chung, S., Lee, B., Seo, A. Y., Chung, J. H., Jung, Y. S., Im, E., et al. (2019) · Aging and disease · doi:10.14336/ad.2018.0324 · Cited by 491
Systematic Review of miRNA as Biomarkers in Alzheimer’s Disease
Swarbrick, S., Wragg, N., Ghosh, S., & Stolzing, A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1500-y · Cited by 350
MicroRNAs in Alzheimer’s Disease
Wang, M., Qin, L., & Tang, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00153 · Cited by 307
Biomarkers for Alzheimer's Disease Diagnosis
Mantzavinos, V., & Alexiou, A. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170203125942 · Cited by 295
Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?
Kumar, S., & Reddy, P. H. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.06.001 · Cited by 289
Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders
van den Berg, M. M. J., Krauskopf, J., Ramaekers, J. G., Kleinjans, J. C. S., Prickaerts, J., & Briedé, J. J. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101732 · Cited by 253
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
Noncoding RNAs in neurodegeneration
Salta, E., & De Strooper, B. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.90 · Cited by 183
MicroRNAs in Neurodegenerative Diseases
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2017.04.002 · Cited by 168
MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease
Kumar, S., Vijayan, M., & Reddy, P. H. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx267 · Cited by 167
Gámez-Valero, A., Campdelacreu, J., Vilas, D., Ispierto, L., Reñé, R., Álvarez, R., Armengol, M. P., Borràs, F. E., & Beyer, K. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0169-5 · Cited by 167
Fan, W., Liang, C., Ou, M., Zou, T., Sun, F., Zhou, H., & Cui, L. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00090 · Cited by 116
Chen, J.-J., Zhao, B., Zhao, J., & Li, S. (2017) · Neural Plasticity · doi:10.1155/2017/7027380 · Cited by 93
Extracellular Vesicles of Alzheimer’s Disease Patients as a Biomarker for Disease Progression
Aharon, A., Spector, P., Ahmad, R. S., Horrany, N., Sabbach, A., Brenner, B., & Aharon-Peretz, J. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02013-1 · Cited by 90
Nie, C., Sun, Y., Zhen, H., Guo, M., Ye, J., Liu, Z., Yang, Y., & Zhang, X. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00438 · Cited by 89
Serum Exosomal miR-223 Serves as a Potential Diagnostic and Prognostic Biomarker for Dementia
Wei, H., Xu, Y., Xu, W., Zhou, Q., Chen, Q., Yang, M., Feng, F., Liu, Y., Zhu, X., Yu, M., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.016 · Cited by 84
Soliman, H. M., Ghonaim, G. A., Gharib, S. M., Chopra, H., Farag, A. K., Hassanin, M. H., Nagah, A., Emad-Eldin, M., Hashem, N. E., Yahya, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910794 · Cited by 81
A Systematic Review of MicroRNA Expression as Biomarker of Late-Onset Alzheimer’s Disease
Herrera-Espejo, S., Santos-Zorrozua, B., Álvarez-González, P., Lopez-Lopez, E., & Garcia-Orad, Á. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01676-9 · Cited by 81
A microRNA signature that correlates with cognition and is a target against cognitive decline
Islam, M. R., Kaurani, L., Berulava, T., Heilbronner, U., Budde, M., Centeno, T. P., Elerdashvili, V., Zafieriou, M., Benito, E., Sertel, S. M., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013659 · Cited by 74
Regev, K., Healy, B. C., Khalid, F., Paul, A., Chu, R., Tauhid, S., Tummala, S., Diaz-Cruz, C., Raheja, R., Mazzola, M. A., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5197 · Cited by 68
Segaran, R. C., Chan, L. Y., Wang, H., Sethi, G., & Tang, F. R. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200121122910 · Cited by 42
Unveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39
“Using Solexa sequencing and qRT-PCR, Dong et al 158 identified blood exosome miRNAs such miR-31, miR-93, miR-143, and miR-146a for AD diagnosis.”
MethodDifferentially Expressed miRNAs in Age-Related Neurodegenerative Diseases: A Meta-Analysis
Noronha, O., Mesarosovo, L., Anink, J. J., Iyer, A., Aronica, E., & Mills, J. D. (2022) · Genes · doi:10.3390/genes13061034 · Cited by 21
Rethinking Alzheimer’s: Novel miRNAs Illuminate a Disease Beyond the Brain
Novotný, J., Čarná, M., Dammer, E., Mao, Z., & Stokin, G. (2025) · doi:10.1101/2025.11.27.690929 · Cited by 1
Rethinking Alzheimer’s: novel miRNAs illuminate a disease beyond the brain
Novotný, J., Čarná, M., Dammer, E., Mao, Z., & Stokin, G. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03487-6 · Cited by 1
Metadata
- Authors
- Dong, H., Li, J., Huang, L., Chen, X., Li, D., Wang, T., Hu, C., Xu, J., Zhang, C., Zen, K., Xiao, S., Yan, Q., Wang, C., & Zhang, C.-Y.
- Venue
- Disease Markers
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-11
- ISSN
- 0278-0240 (ISSN-L)
- 1875-8630
- OpenAlex
- W1481406815
- Cited by
- 211
- References
- 7
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.